Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00506610

A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Flexible Escalating -Dose, Pilot Analgesic Efficacy Study of T-62 in Subjects With Postherpetic Neuralgia

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Pfizer · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether T-62 is effective in providing relief of pain that can occur after an individual experiences a shingles outbreak, which is an infection in adults caused by the same virus that causes chicken pox.

Conditions

Interventions

TypeNameDescription
DRUGT-62

Timeline

First posted
2007-07-25
Last updated
2012-06-07

Locations

8 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00506610. Inclusion in this directory is not an endorsement.